110 related articles for article (PubMed ID: 8246213)
1. Pharmacokinetic and phase I evaluation of carboplatin in dogs.
Page RL; McEntee MC; George SL; Williams PL; Heidner GL; Novotney CA; Riviere JE; Dewhirst MW; Thrall DE
J Vet Intern Med; 1993; 7(4):235-40. PubMed ID: 8246213
[TBL] [Abstract][Full Text] [Related]
2. Effect of whole body hyperthermia on carboplatin disposition and toxicity in dogs.
Page RL; McEntee MC; Williams PL; George SL; Price GS; Novotney CA; Hauck ML; Riviere JE; Dewhirst MW; Thrall DE
Int J Hyperthermia; 1994; 10(6):807-16. PubMed ID: 7884240
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
4. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
Guillet P; Monjanel S; Nicoara A; Duffaud F; Lacarelle B; Bagarry-Liegey D; Durand A; Catalin J; Favre R
Cancer Chemother Pharmacol; 1997; 40(2):143-9. PubMed ID: 9182836
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children.
Doz F; Brugières L; Bastian G; Quintana E; Lemerle J; Zucker JM
Med Pediatr Oncol; 1990; 18(6):459-65. PubMed ID: 2233516
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
[TBL] [Abstract][Full Text] [Related]
9. Infusional carboplatin. Phase I studies of 5-day and 14-day infusions.
Lokich J; Anderson N; Bern M; Zipli T; Gonsalves L; Moore C
Cancer; 1991 Jul; 68(1):68-71. PubMed ID: 2049755
[TBL] [Abstract][Full Text] [Related]
10. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
Rusthoven J; Levin L; Eisenhauer E; Mazurka J; Carmichael J; O'Connell G; Bryson P; Hirte H; Koski B
J Natl Cancer Inst; 1991 Dec; 83(23):1748-53. PubMed ID: 1770554
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
12. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Bailey DB; Rassnick KM; Erb HN; Dykes NL; Hoopes PJ; Page RL
Am J Vet Res; 2004 Nov; 65(11):1502-7. PubMed ID: 15566088
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression.
Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H
Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
15. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
Fujiwara K; Yamauchi H; Sawada S; Koike H; Mohri H; Ohishi Y; Kohno I
Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
17. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer.
Steller MA; Egorin MJ; Trimble EL; Bartlett DL; Zuhowski EG; Alexander HR; Dedrick RL
Cancer Chemother Pharmacol; 1999; 43(2):106-14. PubMed ID: 9923815
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of carboplatin dose escalation in combination chemotherapy with etoposide, bleomycin and GM-CSF support for poor prognosis nonseminomatous germ cell tumors patients.
Tjulandin SA; Stenina MB; Sidorova NJ; Delgado FG; Sokolov AV; Molchanov GV; Ljubimova NV; Garin AM
Neoplasma; 1996; 43(5):347-52. PubMed ID: 8996556
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]